Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin for post-ischemic stroke aphasia
ISRCTN54581790Phase 4Completed
- Sponsor
- Foundation for the Study of Neuroscience and Neuroregeneration
- Start
- Jun 2020
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cerebrolysin in ischemic stroke and aphasia (2 arms), sponsored by Foundation for the Study of Neuroscience and Neuroregeneration. Primary endpoint: Western Aphasia Battery. Started Jun 2020; status: completed.
02
Drugs
cerebrolysin
03
Conditions
ischemic strokeaphasia
Beyond the preview
Go deeper on ISRCTN54581790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN54581790.